Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies
Status:
Withdrawn
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Standard therapy for high-risk or locally advanced salivary gland malignancies is surgery
followed by postoperative radiation therapy. Studies have shown the superiority of combined
modality therapy compared to surgery alone. Despite the addition of postoperative radiation
therapy, the five-year survival for locally advanced salivary gland malignancies is poor
(less than 60%). In salivary gland malignancies, the epidermal growth factor receptor (EGFR)
is expressed in 25-85%; in certain histological types, like salivary duct carcinomas, the
expression is higher. EGFR is a promising target of anticancer therapy. In squamous cell
carcinoma of the head and neck, a phase III trial utilizing cetuximab added to radiation
therapy improved both locoregional control and overall survival compared to radiation alone.
Panitumumab is a novel, human, IgG2 EGFR monoclonal antibody that may be better tolerated and
more efficacious than cetuximab. Here, the investigators hypothesize that the addition of
panitumumab to standard radiotherapy in locally advanced salivary gland malignancies will
improve recurrence-free survival (RFS).
Phase:
Phase 2
Details
Lead Sponsor:
Athanassios Argiris
Collaborators:
University of North Carolina, Chapel Hill University of Pittsburgh